Itco Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 15-11-2024
- Paid Up Capital ₹ 0.10 M
as on 15-11-2024
- Company Age 34 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.22 Cr
as on 15-11-2024
- Revenue 0.83%
(FY 2023)
- Profit -3.46%
(FY 2023)
- Ebitda 9.52%
(FY 2023)
- Net Worth 24.11%
(FY 2023)
- Total Assets 21.32%
(FY 2023)
About Itco Pharmachem
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹6.22 Cr.
Snigdha Basu, Sumit Basu, and Rajnish Hedao serve as directors at the Company.
- CIN/LLPIN
U24110MH1990PTC055576
- Company No.
055576
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Feb 1990
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Itco Pharmachem?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumit Basu  | Director | 26-Feb-1990 | Current |
| Snigdha Basu | Whole-Time Director | 26-Feb-1990 | Current |
| Rajnish Hedao | Whole-Time Director | 26-Feb-1990 | Current |
Financial Performance of Itco Pharmachem.
Itco Pharmachem Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.83% increase. The company also saw a slight decrease in profitability, with a 3.46% decrease in profit. The company's net worth Soared by an impressive increase of 24.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Itco Pharmachem?
In 2023, Itco Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Acropoliis Entertainment Private LimitedActive 18 years 2 months
Snigdha Basu, Sumit Basu and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Standard Chartered Bank Creation Date: 06 Mar 2019 | ₹4.25 Cr | Open |
Standard Chartered Bank Creation Date: 28 Dec 2010 | ₹1.97 Cr | Open |
How Many Employees Work at Itco Pharmachem?
Unlock and access historical data on people associated with Itco Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Itco Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Itco Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
